Literature DB >> 25818429

Effects of mannose density on in vitro and in vivo cellular uptake and RNAi efficiency of polymeric nanoparticles.

Shuang Chu1, Cui Tang2, Chunhua Yin1.   

Abstract

To evaluate the effects of mannose density on in vitro and in vivo cellular uptake and RNA interference (RNAi) efficiency of polymeric nanoparticles (NPs) in macrophages, mannose-modified trimethyl chitosan-cysteine (MTC) conjugates with mannose densities of 4%, 13%, and 21% (MTC-4, MTC-13, and MTC-21) were synthesized. Tumor necrosis factor-alpha (TNF-α) siRNA loaded MTC NPs with particle sizes of ∼150 nm exhibited desired structural stability and effectively protected siRNA from enzymatic degradation. Generally, cellular uptake and RNAi efficiency were affected by mannose density. As expected, MTC-21 NPs presented the maximum in vitro uptake and RNAi efficacy in Raw 264.7 cells among all NPs tested. However, MTC-4 NPs exhibited the optimal in vivo uptake by peritoneal exudate cell macrophages (PECs). In the inflammation model of acute hepatic injury, orally delivered MTC-4 and MTC-13 NPs worked better in silencing TNF-α expression and alleviating liver damage than MTC-21 NPs. As for the ulcerative colitis model, MTC-4 NPs outperformed MTC-13 and MTC-21 NPs with respect to TNF-α knockdown and therapeutic efficacy following oral administration. These results highlighted the importance of ligand density in cellular uptake and RNAi efficiency, which could serve as a guideline in the rational design of targeted nanocarriers for anti-inflammation therapy.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cellular uptake; Gene delivery; Gene silencing; Mannose density; Polymeric nanoparticles

Mesh:

Substances:

Year:  2015        PMID: 25818429     DOI: 10.1016/j.biomaterials.2015.02.044

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  8 in total

Review 1.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

Review 2.  RNA interference-based nanosystems for inflammatory bowel disease therapy.

Authors:  Jian Guo; Xiaojing Jiang; Shuangying Gui
Journal:  Int J Nanomedicine       Date:  2016-10-12

3.  Intranasal Vaccination with Mannosylated Chitosan Formulated DNA Vaccine Enables Robust IgA and Cellular Response Induction in the Lungs of Mice and Improves Protection against Pulmonary Mycobacterial Challenge.

Authors:  Manli Wu; Haoxin Zhao; Min Li; Yan Yue; Sidong Xiong; Wei Xu
Journal:  Front Cell Infect Microbiol       Date:  2017-10-16       Impact factor: 5.293

4.  Co-delivery of polyinosinic:polycytidylic acid and flagellin by poly(lactic-co-glycolic acid) MPs synergistically enhances immune response elicited by intranasally delivered hepatitis B surface antigen.

Authors:  Xiaojing Dai; Jintian He; Ruxia Zhang; Guanghao Wu; Fangfang Xiong; Baohua Zhao
Journal:  Int J Nanomedicine       Date:  2017-09-07

5.  Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy.

Authors:  Haiying Hua; Nan Zhang; Dan Liu; Lili Song; Tuanbing Liu; Shasha Li; Yongxing Zhao
Journal:  Int J Nanomedicine       Date:  2017-10-25

Review 6.  Recent Progress in the Diagnosis and Precise Nanocarrier-Mediated Therapy of Inflammatory Bowel Disease.

Authors:  Liucan Wang; Min Yu; Hua Yang
Journal:  J Inflamm Res       Date:  2021-04-29

7.  Homing in on an intracellular target for delivery of loaded nanoparticles functionalized with a histone deacetylase inhibitor.

Authors:  Jie Zhang; Yaling Shi; Yueqin Zheng; Chengcheng Pan; Xiaoying Yang; Taoyan Dou; Binghe Wang; Wen Lu
Journal:  Oncotarget       Date:  2017-08-07

Review 8.  Targeting of Hepatic Macrophages by Therapeutic Nanoparticles.

Authors:  Clara I Colino; José M Lanao; Carmen Gutierrez-Millan
Journal:  Front Immunol       Date:  2020-03-04       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.